Company Filing History:
2 out of 1,743 
1 out of 1 
1 out of 3 Years Active: 2015-2016
Title: Eric Rubinstein: Innovator in Cancer Management
Introduction
Eric Rubinstein is a notable inventor based in Villejuif, France. He has made significant contributions to the field of cancer management, particularly through his innovative approaches targeting the Co-029 protein. With a total of 2 patents, Rubinstein's work is paving the way for advancements in cancer treatment and prevention.
Latest Patents
Rubinstein's latest patents focus on methods for cancer management targeting Co-029. The first patent discloses a Co-029 inhibitor designed to inhibit the migration of cancer cells that express Co-029. This invention aims to provide a treatment for cancer and prevent cancer metastasis. Additionally, the patent includes pharmaceutical compositions comprising the Co-029 inhibitor and offers Co-029 antibodies. Furthermore, it outlines methods for predicting a patient's response to treatment with a Co-029 inhibitor, diagnosing cancer in patients, and predicting survival rates for cancer patients.
Career Highlights
Throughout his career, Eric Rubinstein has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Paris XI Paris Sud. His experience in these organizations has contributed to his expertise in cancer research and management.
Collaborations
Rubinstein has collaborated with notable colleagues, including Céline Greco and François Le Naour. These partnerships have further enhanced his research and development efforts in the field of cancer treatment.
Conclusion
Eric Rubinstein's innovative work in cancer management, particularly through his patents targeting Co-029, showcases his commitment to improving patient outcomes. His contributions to the field are significant and continue to influence cancer research and treatment strategies.